Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 2 de 2
1.
PLoS One ; 8(5): e62452, 2013.
Article En | MEDLINE | ID: mdl-23658728

The use of ß-blockers is mandatory for counteracting heart failure (HF)-induced chronic sympathetic hyperactivity, cardiac dysfunction and remodeling. Importantly, aerobic exercise training, an efficient nonpharmacological therapy to HF, also counteracts sympathetic hyperactivity in HF and improves exercise tolerance and cardiac contractility; the latter associated with changes in cardiac Ca(2+) handling. This study was undertaken to test whether combined ß-blocker and aerobic exercise training would integrate the beneficial effects of isolated therapies on cardiac structure, contractility and cardiomyocyte Ca(2+) handling in a genetic model of sympathetic hyperactivity-induced HF (α2A/α2C- adrenergic receptor knockout mice, KO). We used a cohort of 5-7 mo male wild-type (WT) and congenic mice (KO) with C57Bl6/J genetic background randomly assigned into 5 groups: control (WT), saline-treated KO (KOS), exercise trained KO (KOT), carvedilol-treated KO (KOC) and, combined carvedilol-treated and exercise-trained KO (KOCT). Isolated and combined therapies reduced mortality compared with KOS mice. Both KOT and KOCT groups had increased exercise tolerance, while groups receiving carvedilol had increased left ventricular fractional shortening and reduced cardiac collagen volume fraction compared with KOS group. Cellular data confirmed that cardiomyocytes from KOS mice displayed abnormal Ca(2+) handling. KOT group had increased intracellular peak of Ca(2+) transient and reduced diastolic Ca(2+) decay compared with KOS group, while KOC had increased Ca(2+) decay compared with KOS group. Notably, combined therapies re-established cardiomyocyte Ca(2+) transient paralleled by increased SERCA2 expression and SERCA2:PLN ratio toward WT levels. Aerobic exercise trained increased the phosphorylation of PLN at Ser(16) and Thr(17) residues in both KOT and KOCT groups, but carvedilol treatment reduced lipid peroxidation in KOC and KOCT groups compared with KOS group. The present findings provide evidence that the combination of carvedilol and aerobic exercise training therapies lead to a better integrative outcome than carvedilol or exercise training used in isolation.


Adrenergic beta-Antagonists/pharmacology , Carbazoles/pharmacology , Exercise Therapy , Heart Failure/therapy , Myocardial Contraction , Propanolamines/pharmacology , Adrenergic beta-Antagonists/therapeutic use , Animals , Blood Pressure , Calcium Signaling , Carbazoles/therapeutic use , Carvedilol , Cells, Cultured , Combined Modality Therapy , Drug Evaluation, Preclinical , Exercise Tolerance , Heart Failure/metabolism , Heart Failure/physiopathology , Heart Rate , Lipid Peroxidation , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Myocardium/metabolism , Myocardium/pathology , Myocytes, Cardiac/metabolism , Oxidative Stress , Physical Conditioning, Animal , Propanolamines/therapeutic use , Sarcoplasmic Reticulum Calcium-Transporting ATPases/metabolism , Ventricular Remodeling
2.
J Mol Cell Cardiol ; 45(2): 240-9, 2008 Aug.
Article En | MEDLINE | ID: mdl-18632114

beta-blockers, as class, improve cardiac function and survival in heart failure (HF). However, the molecular mechanisms underlying these beneficial effects remain elusive. In the present study, metoprolol and carvedilol were used in doses that display comparable heart rate reduction to assess their beneficial effects in a genetic model of sympathetic hyperactivity-induced HF (alpha(2A)/alpha(2C)-ARKO mice). Five month-old HF mice were randomly assigned to receive either saline, metoprolol or carvedilol for 8 weeks and age-matched wild-type mice (WT) were used as controls. HF mice displayed baseline tachycardia, systolic dysfunction evaluated by echocardiography, 50% mortality rate, increased cardiac myocyte width (50%) and ventricular fibrosis (3-fold) compared with WT. All these responses were significantly improved by both treatments. Cardiomyocytes from HF mice showed reduced peak [Ca(2+)](i) transient (13%) using confocal microscopy imaging. Interestingly, while metoprolol improved [Ca(2+)](i) transient, carvedilol had no effect on peak [Ca(2+)](i) transient but also increased [Ca(2+)] transient decay dynamics. We then examined the influence of carvedilol in cardiac oxidative stress as an alternative target to explain its beneficial effects. Indeed, HF mice showed 10-fold decrease in cardiac reduced/oxidized glutathione ratio compared with WT, which was significantly improved only by carvedilol treatment. Taken together, we provide direct evidence that the beneficial effects of metoprolol were mainly associated with improved cardiac Ca(2+) transients and the net balance of cardiac Ca(2+) handling proteins while carvedilol preferentially improved cardiac redox state.


Adrenergic beta-Antagonists/pharmacology , Heart Failure/drug therapy , Heart Failure/physiopathology , Intracellular Fluid/physiology , Receptors, Adrenergic, beta/metabolism , Animals , Carbazoles/therapeutic use , Carvedilol , Disease Models, Animal , Heart Failure/genetics , Heart Failure/mortality , Heart Function Tests , Hemodynamics/drug effects , Hemodynamics/genetics , Intracellular Fluid/drug effects , Intracellular Fluid/metabolism , Male , Metoprolol/therapeutic use , Mice , Mice, Congenic , Mice, Inbred C57BL , Mice, Knockout , Myocardial Contraction/drug effects , Myocardial Contraction/genetics , Propanolamines/therapeutic use , Random Allocation
...